The first edition of Oncogenes (1989) focused on several of the better known transforming mechanisms and surveyed a spectrum of solid tumors and hematologic malignancies. Several of the nearly 50 known oncogenes most relevant to human disease were examined. In contrast, this volume presents a very different profile and balance of subject material that reflects the rapidly changing field of molecular oncology and its newly emerging concepts. Among the most important discoveries of the past 4 years are the identification of nearly a dozen different tumor suppressor genes and the finding of an...

Gastric cancer has been one of the great malignant scourges affecting man- kind for as long as medical records have been kept. Until operative resection pioneered by Bilroth and others became available, no effective treatment was feasible and death from cancer was virtually inevitable. Even with resection by total gastrectomy, the chances of tumor eradication remained small. Over recent years, however, the situation has been changing. Some changes have resulted from better understanding of the disease, early detec- tion, and better management techniques with applied clinical research, but the...

In Breast Cancer: Cellular and Molecular Biology Kluwer Academic Pub- lishers, 1988], we tried to present an introduction to the emerging basic studies on steroid receptors, oncogenes, and growth factors in the regulation of normal and malignant mammary epithelium. The response to this volume was superb, indicating a tremendous interest in basic growth regulatory mechanisms governing breast cancer and controlling its malignant progres- sion. In the two years since its publication, much new and exciting in- formation has been published and the full interplay of regulatory mechanisms is now...

In recent years, there have been major advances in the treatment of patients with gynecologic malignancies. Perhaps the biggest advances have been in the area of ovarian cancer. Gynecologic Oncology focuses primarily upon this malignancy.
This volume discusses cytoreductive surgery; screening for ovarian cancer; chemotherapy; new chemotherapeutic drugs; the controversy regarding the role of high-dose chemotherapy in gynecologic cancers; the hereditary basis for gynecologic malignancies; molecular genetics; molecular biology and new biologic therapies.
Other topics covered...

The field of genito-urinary oncology is rapidly evolving at virtually every level. Significant advances have been made in our understanding of the molecular and cellular events which contribute to the generation of GU malignancies. At the same time, similar advances have been made in the clinical arena which have improved the diagnosis and treatment of urologic cancers.
This volume attempts to summarize those advances which most impact us as clinicians, and has been divided into three sections. Section One, Diagnostic advances: the use of molecular medicine in the diagnosis and...

Infection is a major cause of morbidity and mortality in patients with neoplastic disease because of compromised host defenses. These defects result in an increased risk of infection and its complications. The nature of the underlying malignancy, the immunodeficiencies associated with it, and the treatments directed against it are all important determinants of infection. In recent years, the introduction of more intensive chemotherapeutic regimes and the widespread use of bone marrow and peripheral stem cell transplantation have changed the pattern of infection in many patients. Furthermore,...

One of the most exciting areas of cancer research now is the development of agents which can target signal transduction pathways that are activated inappropriately in malignant cells. The understanding of the molecular abnormalities which distinguish malignant cells from their normal counterparts has grown tremendously.
This volume summarizes the current research on the role that signal transduction pathways play in the pathogenesis of cancer and how this knowledge may be used to develop the next generation of more effective and less toxic anticancer agents.
Series Editor comments:...

- Discusses the latest drug treatments in the field - Gleevec arranged a bulk sale for this title

- Written by leaders in the industry

Our limited understanding of cellular regulatory signal-transduction-networks has been a barrier to progress in improving the overall cure-rate of human cancers. Delineation of the physiologic roles of the specific regulatory signaling components, with known association with metastatic phenotypes, is a highly promising area which will likely provide the next generation of targeted strategies in the future of molecular cancer medicine. These signaling components are likely to be used in diagnosis, prognosis, and as novel targets for therapeutic development.

This book brings...

Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good indepth reviews of cancer topics, and pub lished symposium lectures are often the best overviews available. Unfortu nately, these reviews and supplements appear sporadically, and the reader can never be sure...